K2 Amp Rictor 90 Xti

[Pinkie Mclucas]

Recombinantantibodies offer several key advantages compared to traditional antibodies. These include superior lot-to-lot consistency, continuous supply, and animal-free manufacturing. As such, recombinant antibodies are seeing increased use for scientific research, especially as a means of addressing the ongoing reproducibility crisis.

Traditional polyclonal and monoclonal antibodies are the product of normal B cell development and genetic recombination. They are generated by immunizing an animal with an antigen to elicit an immune response. While polyclonal antibodies are secreted by many different B cell clones and recognize multiple antigenic epitopes, monoclonals originate from a single B cell clone and are specific for just one epitope.

Recombinant antibodies are monoclonal, but their production involves in vitro genetic manipulation. After cloning the antibody genes into an expression vector, this is then transfected into an appropriate host cell line for antibody expression. Mammalian cell lines are most commonly used for recombinant antibody production, although cell lines of bacterial, yeast, or insect origin are also suitable.

Because recombinant antibody production involves sequencing the antibody light and heavy chains, it is a highly controlled and reliable process. In contrast, hybridoma-based systems for producing monoclonal antibodies are subject to genetic drift and instability, increasing the potential for lot-to-lot variability or loss of antibody expression. Recombinant antibodies are highly consistent from lot to lot, thereby ensuring reproducible experimental results.

In vitro methods for producing antibodies are amenable to large-scale production, meaning antibody availability is unlikely to become a limiting factor. Moreover, since the recombinant antibody sequence is known, continuity of supply is assured; in situations where an antibody will be used to support large, long-term studies, this can be an especially critical factor.

Cell growth is a fundamental biological process whereby cells accumulate mass and increase in size. The mammalian TOR (mTOR) pathway regulates growth by coordinating energy and nutrient signals with growth factor-derived signals (1). mTOR is a large protein kinase with two different complexes. One complex contains mTOR, GβL and raptor, which is a target of rapamycin. The other complex, insensitive to rapamycin, includes mTOR, GβL, Sin1, and rictor (1). The mTOR-rictor complex phosphorylates Ser473 of Akt/PKB in vitro (2). This phosphorylation is essential for full Akt/PKB activation. Furthermore, an siRNA knockdown of rictor inhibits Ser473 phosphorylation in 3T3-L1 adipocytes (3). This complex has also been shown to phosphorylate the rapamycin-resistant mutants of S6K1, another effector of mTOR (4).

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

The site is secure.

The ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes. Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase. We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its associated protein rictor are necessary for Ser473 phosphorylation and that a reduction in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector. The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1. Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.

Mammalian target of rapamycin (mTOR) controls cell growth and proliferation via the raptor-mTOR (TORC1) and rictor-mTOR (TORC2) protein complexes. Recent biochemical studies suggested that TORC2 is the elusive PDK2 for Akt/PKB Ser473 phosphorylation in the hydrophobic motif. Phosphorylation at Ser473, along with Thr308 of its activation loop, is deemed necessary for Akt function, although the regulatory mechanisms and physiological importance of each phosphorylation site remain to be fully understood. Here, we report that SIN1/MIP1 is an essential TORC2/PDK2 subunit. Genetic ablation of sin1 abolished Akt-Ser473 phosphorylation and disrupted rictor-mTOR interaction but maintained Thr308 phosphorylation. Surprisingly, defective Ser473 phosphorylation affected only a subset of Akt targets in vivo, including FoxO1/3a, while other Akt targets, TSC2 and GSK3, and the TORC1 effectors, S6K and 4E-BP1, were unaffected. Our findings reveal that the SIN1-rictor-mTOR function in Akt-Ser473 phosphorylation is required for TORC2 function in cell survival but is dispensable for TORC1 function.

Mammalian target of rapamycin complex 2 (mTORC2) and integrin-linked kinase (ILK) are regulators of Akt Ser473 phosphorylation in cancer cells (1, 2). Rictor and mSin1 are essential to the Akt Ser473 kinase functionality of mTORC2 in Drosophila and mammalian cells (3, 4). mTORC2 is considered to be rapamycin insensitive, although chronic exposure to rapamycin or its analogues may impede its formation, leading to inhibition of Akt Ser473 phosphorylation in some cells (5). However, rapamycin also increases Akt Ser473 phosphorylation in human cancer cell lines (6), suggesting the existence of additional kinases capable of phosphorylating Akt on Ser473. ILK represents a physiologically relevant candidate responsible for this activity.

To better understand the molecular events involved in ILK-mediated signaling, we used a combined immunoprecipitation/mass spectrometry (MS) approach to identify novel ILK-mediated protein-protein interactions. One of the identified interacting proteins was rictor, which we now show to interact directly with ILK to regulate Akt Ser473 phosphorylation. We probed several human cancer cell lines with small interfering RNA (siRNA) to elucidate the relative contributions of mTORC2 and ILK in the promotion of Akt Ser473 phosphorylation. Our results show crucial roles for the ILK/rictor complex in the regulation of Akt Ser473 phosphorylation and cancer cell survival.

Cell harvest and lysis. Cells were harvested and lysed as described previously (7, 10). For immunoprecipitation experiments, cell lysis was carried out using a buffer containing 0.3% CHAPS (5). Protein concentrations were determined using the BCA microplate assay (Pierce Biotechnology).

Isolation of cytoskeleton. Cytoskeletal extracts were prepared as described (12) with modifications. Briefly, cells were rinsed with 10 mL of cytoskeleton-stabilizing buffer. The Triton-soluble protein fraction was extracted with 6 mL CSB, containing 1% Triton X-100 and protease inhibitors for 2 min at 37C. The cytoskeleton was collected in 1 mL of extraction buffer, sonicated, and dialyzed overnight.

Immunoprecipitation and coimmunoprecipitation. Details for the anti-FLAG immunoprecipitates are described elsewhere.44I. Dobreva, A. Fielding, L.J. Foster, S. Dedhar. Mapping the integrin-linked kinase interactome using SILAC. Journal of Proteome Research. In press, 2008.

Western blotting. Immunoblotting was carried out as previously described (10). For detection of mTOR and rictor, proteins were separated on 4% to 15% SDS-PAGE gradient gels (Bio-Rad Laboratories). Proteins were visualized by chemiluminescence using supersignal (Pierce) or by fluorescence using the Odyssey system (Li-Cor Biosciences). Adobe Photoshop was used for image manipulations. All image processing was applied to the whole image and levels were adjusted in a linear fashion. Densitometric analyses were carried out on raw, scanned images using the Quantity One software package (Bio-Rad Laboratories).

3a8082e126